Go-ahead for Possis stroke trials:
This article was originally published in Clinica
Executive Summary
Possis Medical has the go-ahead for US trials of its AngioJet clot-busting system for treating stroke caused by blocked carotid arteries. Feasibility studies will consist of 10 patients at two sites. The company has filed a humanitarian device exemption application with the FDA to sell its Perma-Flow coronary bypass graft to a limited number of patients. This will not necessitate new trials of the device as reported in Clinica No 782, p 19.
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.